Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$FUSZD - VERB Partnering with another Multi-Billion Dollar Tech Powerhouse as they Announce LOI w/ GettyImages for Upcoming Video Store Ecosystem! GettyImages has a near $3 Billion Valuation
https://nfusz.com/wp-content/uploads/2019/02/Verb-Getty_PR_CLEAN.pdf
https://www.google.com/amp/s/nypost.com/2018/09/04/getty-family-takes-full-control-of-getty-images/amp/
EMIS working with NVO. Right now they get a 2.5% royalty on a drug that may generate up to $10 billion a year. They are working with NVO on other drugs as well which will bring in more royalties/upfront payments
Great article. I especially like the section where they cite EMIS:
"A breakthrough for Novo Nordisk
We made the decision to try to develop oral protein-based therapies after failing in our efforts to develop inhaled forms more than a decade ago. Although we were the first to show that insulin can indeed be taken orally, the technology falls short of this being a viable treatment for the millions of people using insulin around the world (you can read an article I wrote specifically about oral insulin).
The better news is that when working with GLP-1 – a class of molecules traditionally used in the treatment of type 2 diabetes and obesity - we have recently succeeded and shown that an analogue of the GLP-1 hormone can be taken in a tablet. The key was to design GLP-1 so that it remains stable in the stomach and combine it with a carrier molecule known as SNAC, provided by our partner Emisphere. In doing this, we developed the world’s first peptide in a tablet for the treatment of diabetes.
As a scientist, this is very exciting and I hope that in the longer-term, the SNAC technology platform can be applied to a broader range of biological medications that address not only diabetes, but also other serious chronic diseases."
CLSD $1.74 +20% ..FDA accepted NDA and PDUFA date is October 19, 2019
$MCGI IS RUNNING TO 00s quivklyyy !
IGXT .70 PDUFA April 1st there is no better Bio play right now..
CURRENT PRESENTATION
http://s2.q4cdn.com/790425727/files/doc_presentations/2018/11/30/Nov-2018-IntelGenx-Investor-Presentation.pdf
BOSC getting legs. Possible shakeup on the Board of Directors.
CLSD on strong watch ~ NDA submitted on 12/19/2019 .. FDA news anytime now
Is BITCOIN ETF coming? Never been so close as of these days. RIOT MARA OSTK BYSD
$CIIX CBD Biotech
$FUSZD - Check Out this Tagged Video of what Happens with the rest of the Tech world finds out VERB Tagg Tech is already integrated into Microsoft, Salesforce, Oracle, Adobe, Marketo, Facebook, Instagram, Netsuite and Gartner
https://video.nfusz.com/player/EF83XRB2
NSPX for Monday gain!! IMO NSPX shares are maxed and awaiting new/filings very soon!!
INSYS Therapeutics, Inc. $INSY Investor Presentation 2019 https://insysrx.gcs-web.com/static-files/24047686-5537-4cfc-b8e1-653c1d966e42
$CIIX Cannabidiol (CBD) is one of the most important healing substances in the hemp plant with a strong anti-inflammatory effect without a psychotropic (narcotic) effect.
http://chineseinvestors.com/opportunities-in-cbd/
CBD Biotech $CIIX Market Cap $20.32 million
https://www.marketbeat.com/stocks/OTCMKTS/CIIX/
$INSY "SYNDROS® is a cannabinoid medicine used in adults to treat:
Loss of appetite (anorexia) in people with AIDS (Acquired Immune Deficiency Syndrome) who have lost weight
Nausea and vomiting caused by anti-cancer medicine (chemotherapy) in people whose nausea and vomiting have not improved with usual anti-nausea and vomiting medicines
SYNDROS® is the first and only FDA-approved liquid dronabinol, which allows for fast absorption, flexible dosing and a potential solution for patients who may prefer a liquid medication."
https://www.insysrx.com/products/approved
$CIIX CBD HEMP technical breakout coming imo
*** EDGE 0.41 R/M PENDING >>> CAN KICK IN ANY WEEK ANY DAY! MULTIPLER TICKET IMHO. READ >>>>>>>
Therapeutics, Privately Held PDS Biotech Announce Reverse Merger
What Happened
Edge Therapeutics announced its intention to merge with the privately held, clinical-stage cancer immunotherapy company PDS Biotechnology Corp. The boards of both companies approved the proposed transaction, the companies said in a joint press release.
A reverse merger deal is a transaction in which an active private company merges with a dormant public company in a bid to go public without having to go through the arduous route of a traditional initial public offering.
Edge announced a comprehensive review of strategic alternatives in April in a bid to maximize shareholder value. The decision followed a failed late-stage trial of its aneurysmal subarachnoid hemorrhages treatment candidate, which subsequently forced the company to announce layoffs.
Why It's Important
Edge sees the merger as facilitating the creation of a publicly traded immuno-oncology company that develops novel products to treat early- and late-stage cancer.
PDS Biotech's lead candidate PDS101 has demonstrated immunotherapeutic anti-cancer activity and a favorable safety profile in early stage cervical cancer in a Phase 1/2 clinical trial.
"We expect that the combined company will have the financial resources and experienced leadership to accomplish our key near-term objectives: first, to initiate multiple late-stage clinical studies for our lead product candidate PDS0101; and second, to further advance our preclinical programs toward the clinic," PDS CEO Frank Bedu-Addo said in a statement.
What's Next
The deal is expected to close in the first quarter of 2019.
Following the consummation of the deal, the merged entity will function under the name PDS Biotechnology Corp., with the shares of the combined company to be listed on the Nasdaq under a new ticker symbol to be announced at a later date.
On the pipeline front, the combined company plans to initiate Phase 2b/3 clinical trials of PDS101 in HPV-associated cancers.
EDGE 1000% TURN AROUND PIC FOR NEXT WEEKS/MONTH IMHO! MY NEXT BIOTECH MULTIPLER
Coeptis who has partnered in USA with KTOV has issued a private placement at link below.
https://www.sec.gov/Archives/edgar/data/1760174/000176017418000001/xslFormDX01/primary_doc.xml
Saw that Coeptis who made a deal with KTOV also made a deal with Ciron Pharmaceuticals in November 2017 at link below.
https://eprnews.com/coeptis-pharmaceuticals-signs-multi-product-co-development-agreement-262018/
Also Coeptis bought Elto Pharma in November 2018 at link below.
https://finance.yahoo.com/news/coeptis-pharma-enters-agreement-acquire-125525599.html
KTOV got a USA partnership for their new FDA approved drug Consensi but no buyout. Stock was up 44% but warrants were down 17%. Would be better to just buy stock since warrants expire November 25 2020. They are developing a new cancer drug also in the future so some risk for sure long term.
https://finance.yahoo.com/news/kitov-signs-marketing-distribution-agreement-121900751.html
CTRX 1.08 will explode here,was $16.05 52wh
Positive Article on MICT on January 1 2019 at link below.
https://nasdaqnewsreports.blogspot.com/2019/01/countdown-to-165-tender-offer-on-mict.html
EPAZ What’s Propelling EPAZZ INC (OTCMKTS:EPAZ) After Higher Shorts Reported?
The stock of EPAZZ INC (OTCMKTS:EPAZ) registered an increase of 143.35% in short interest. EPAZ’s total short interest was 49,400 shares in December as published by FINRA. Its up 143.35% from 20,300 shares, reported previously. With 165,400 shares average volume, it will take short sellers 0 days to cover their EPAZ’s short positions.
The stock increased 13.16% or $0.0025 during the last trading session, reaching $0.0215. About 77,944 shares traded.
NEPH-
Press Release: Nephros Announces Acquisition of Biocon
1/2/19, 6:30 AM
Nephros Announces Acquisition of Biocon
Adds Growing Water Filtration Business in Food Service, Hospitality, and Industrial Markets
Expands Water Filter Product Portfolio
ACST .8319,beautiful chart daily and weekly,,wow,,https://stockcharts.com/freecharts/gallery.html?acst
ACST~~nothing above .81,on high buy alert
ACST crazy bid at .79.39,BOOMMMMMMMMMMMM folks
CCCL~~hit 1.95 today from .80 last week
ACST~~.huge news,,77 buy asap,after .81 ,crazy run
$NIMU - Non-Invasive Monitoring Systems, Inc. Signs Agreement to Combine w/ IRA Financial Group LLC @ IRA Financial Trust Company! 12,000 retirement account clients invest in excess of $3 billion of retirement funds
https://finance.yahoo.com/news/non-invasive-monitoring-systems-inc-135249922.html
VTVT~~nice this morning
ACST~~HUGE NEWS.77 ,after .81 (above MA 100, Ma 50, MA 200 )will run crazy folks
https://stockcharts.com/h-sc/ui?s=acst&p=D&yr=0&mn=6&dy=0&id=p31873288935
CCCL .80 nasdaq,watch very closely,i'ts hot ,will run crazy again,$6+++
RTTR~~.62.after .67 a go ,nasdaq
MKGI~~1.20,tomorrow good
YGYI~~5.64,watch to break 6.52 and after will break crazy http://www.stockta.com/cgi-bin/analysis.pl?symb=YGYI&cobrand=&mode=stock
VTVT will continue monday ,possible to break $3.50
Thank you m1999, feel free to share your trades ideas
So SO undervalued
Spectrum Global Solutions, Inc. (SGSI) Displays Capability to be One Stop Shop for 5G
http://www.networknewswire.com/spectrum-global-solutions-inc-sgsi-displays-capability-to-be-one-stop-shop-for-5g/
December 27, 2018
MICT 1.23 +43% , could be $1.65 and north imo. I pointed months ago that ER alone confirmed much higher prices
BOSC yep. They had several Contracts this year. A tiny solid Company
MICT $1.15 +33% PM.
BNN Technology will purchase up to 20% of MICT's common stock for $1.65/share. it's a complex merger as I mentioned before. All of the shares to be issued by GFH are valued at $1.65 per share, representing a GFH equity valuation of approximately $283 million.
MICT +200%, I'm waiting for the other oversold companies to do even more in 2019, DTEA, NDRA...
Ash any idea on what this new company valuation will look like. My average is $1.20 and may still keep some of my shares.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |